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Abstract
Background: Several lines of evidence have supported possible roles of the sigma receptors in
the etiology of schizophrenia and mechanisms of antipsychotic efficacy. An association study
provided genetic evidence that the sigma receptor type 1 gene (SIGMAR1) was a possible
susceptibility factor for schizophrenia, however, it was not replicated by a subsequent study. It is
necessary to evaluate further the possibility that the SIGMAR1 gene is associated with susceptibility
to schizophrenia.
Methods: A case-control association study between two polymorphisms of the SIGMAR1 gene, G-
241T/C-240T and Gln2Pro, and schizophrenia in Japanese population, and meta-analysis including
present and previous studies.
Results: There was no significant association of any allele or genotype of the polymorphisms with
schizophrenia. Neither significant association was observed with hebephrenic or paranoid subtype
of schizophrenia. Furthermore, a meta-analysis including the present and previous studies
comprising 779 controls and 636 schizophrenics also revealed no significant association between
the SIGMAR1 gene and schizophrenia.
Conclusion:  In view of this evidence, it is likely that the SIGMAR1  gene does not confer
susceptibility to schizophrenia.
Background
Sigma receptors were originally designated as a subtype of
opioid receptors to mediate psychotomimetic actions of
certain opioids such as N-allylnormetazocine [1], but now
they has been defined as non-opiate and non-phencyclid-
ine binding sites [2]. Sigma receptors are expressed in
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various tissues and supposed to be involved in diverse
physiological functions. Especially, substantial roles of
sigma receptors in pathogenesis of psychoses including
schizophrenia have been suggested by many preclinical
and clinical studies. In preclinical studies, putative sigma
receptor antagonists including BMY-14802 and NE-100
improved two classes of animal models of schizophrenia,
behavioral sensitization to psychostimulants [3–5] and
phencyclidine-induced cognitive dysfunction [6]. Binding
studies revealed that sigma receptors are expressed
densely in mesolimbic and mesocortical areas including
cortex and hippocampus [7,8], where structural abnor-
malities were reported in schizophrenic brains. In addi-
tion, postmortem studies showed a reduced sigma
receptor density in the brain of schizophrenia compared
to that of controls [9,10]. In clinical trials, putative selec-
tive antagonists of sigma receptors, such as SL 82.0715
and panamesine, showed successful therapeutic effects for
schizophrenia [11–13]. Most conventional neuroleptics
showed a significant affinity to sigma receptors. Among
them, haloperidol, which has a potent antipsychotic
effects in treatment of schizophrenia, showed a most
potent affinity to sigma receptors [7].
Based on these rationales, Ishiguro et al. [14] screened
promoter and exonic regions of sigma receptor type 1
gene (SIGMAR1 or SR-BP1, OMIM No. *601978), and
found two polymorphisms, G-241T/C-240T (rs1799729)
and Gln2Pro (A61C, rs1800866). They showed that the
two polymorphisms were in complete linkage disequilib-
rium with each other, and a significant association
between the TT-241-240/Pro2 haplotype and schizophre-
nia in a Japanese population (odds ratio = 1.27, P = 0.04).
However, this result was not replicated by a subsequent
study. Thus, Ohmori et al. [15] examined an association
study using the same polymorphisms of the SIGMAR1
gene and found no significant difference in the allelic or
genotypic distribution between schizophrenic patients
and controls. They found slight increased homozygosity
for TT-241-240 and Pro2 in schizophrenics compared
with controls (P = 0.045), but the significance did not
remain after a Bonferoni correction was applied to avoid
false results. Therefore, it should be necessary to clarify
further whether TT-241-240/Pro2 haplotype of the
SIGMAR1 gene is a risk factor for susceptibility of schizo-
phrenia. To this end, we examined association study using
these polymorphisms of the SIGMAR1  gene in schizo-
phrenia in Japanese population and meta-analysis of the
present and previous results.
Methods
Subjects
Patient with schizophrenia and control subjects were
recruited from the middle western area of Japan. They
were provided with information about this study and gave
their written informed consent to participate. A total of
198 schizophrenia patients (106 men and 92 women ;
mean age, 45.1 ± 12.5 y) fulfilling the international statis-
tical classification of disease, revision 10 (ICD-10) diag-
nostic criteria for schizophrenia were registered in five
hospitals: Okayama university graduate school of medi-
cine and dentistry, Zikei hospital, Kibougaoka hospital,
Aoyama hospital, Yuai hospital. Assessment for diagnosis
and subtypes of schizophrenia was carried out by two
trained psychiatrists on the basis of all available informa-
tion. Schizophrenia subtypes included 90 participants of
the paranoid type, 107 participants of the hebephrenic
type and 2 of the catatonic type. A total of 206 healthy vol-
unteers recruited primarily from medical staff were exam-
ined as age- and gender-matched controls (106 men and
100 women ; mean age, 42.1 ± 13.3 y). Only unaffected
subjects who had no known past and family history of
major psychiatric disorders were included in this study.
This study was approved by the Ethics Committee of all
five hospitals.
Mutation screening and genotyping
The genomic DNA was extracted from peripheral leuko-
cytes using standard procedures. 5' flanking region (up to
-585 bp) and each of the four exons with exon-intron
boundary of the SIGMAR1  gene was amplified by
polymerase chain reaction (PCR) in a total volume of 15
µl with 10% dimethyl sulfoxide and 0.75 units superTaq
DNA polymerase (Sawady Technology, Japan) in the reac-
tion mixture using the corresponding primer pairs (for 5'
flanking to exon3; 5'-TGGTGGAAGGTGCCAGAG
ATGA-3' (position of NT 8413 is 34626978-99),
5'-GCTCCCCTCCACTCGACAGTCC-3' (34628383-60),
for exon 4; 5'-GAGACGGTAGTACACGGGCCTGGTG-3'
(34625854-30), 5'-GTTAGTGAGTCAAGCTGTGATGTGT-3'
(34625318-42). The PCR products from 25 subjects (15
schizophrenics and 10 controls) were directly sequenced
to screen novel polymorphism (sequence primer for 5'
flanking to exon3, 5'-TCCCCTCCACTCGACAGTCCTGTG-3'
(34628379-56), 5'-TGACATCTGCCGCTGGGCGACTTG-3'
(34627903-880), 5'-CGAAGGCGCCATCCCCGGACCTAG-3'
(34627428-405), and for exon 4, 
5'-GTCAAGCTGTGATGTGTGTGTCTG-3' (34625326-49),
5'-GGTAGTACACGGGCCTGGTGAGGC-3' (34625849-26)).
For genotype of G-241T/C-240T and Gln2Pro polymor-
phism, PCR amplifications were carried out using each
pair of the primers for the targeted regions of the SIMAR1
gene according to Ishiguro et al. [14], and PCR products
were digested by restriction enzyme of Pst I and Hha I for
G-241T/C-240T and Gln2Pro, and were separated on 2%
and 4.5 % of NuSieve GTG agarose gel, respectively.
Statistical analysis
Deviation of the genotype counts from the Hardy-Wein-
berg equilibrium was tested using a chi-square goodness-BMC Psychiatry 2003, 3 http://www.biomedcentral.com/1471-244X/3/13
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of-fit test. The statistical significance of differences in the
genotype and allele frequencies between patients and con-
trols were tested by Chi square test at a significance level
of .05 two-tailed. For meta-analysis, numbers of each gen-
otype or each allele of three studies by Ishiguro et al. [14],
Ohmori et al. [15] and us were added, and were analysed
by by Chi square test. Statistical power analysis was exam-
ined using software G*Power (version 2.1.2) [16].
Results and Discussion
Screening of 5' promoter region and four exons of the
SIGMAR1 gene identified the two previously reported pol-
ymorphisms, G-241T/C-240T and Gln2Pro, but not any
novel one. The genotypic distributions for patient and
control groups did not deviate significantly from the
Hardy-Weinberg equilibrium at the two polymorphisms
of the SIGMAR1 gene. Frequencies of each genotype and
allele of the polymorphisms were similar to those of pre-
vious studies. In consistent with the previous studies, G-
241T/C-240T and Gln2Pro polymorphisms showed com-
plete linkage disequilibrium with each other, and resulted
in two haplotypes, GC-241-240/Gln2 and TT-241-240/
Pro2. Subsequently, results of only Gln2 Pro was shown
in table 1. The present study revealed that there was no
significant difference in the genotype frequencies (x2 =
0.05, d.f. = 2, P = 0.97) or allele frequencies (x2 = 0.02, d.f.
= 1, P = 0.88) of Gln2Pro polymorphism between schizo-
phrenia patients and controls. No association was
observed between the polymorphism and any of the diag-
nostic subtypes, hebephrenic type (genotype, x2 = 0.01,
d.f. = 2, P = 0.99, allele, x2 = 0.00, d.f. = 1, P = 1.00) and
paranoid type (genotype, x2 = 0.06, d.f. = 2, P = 0.97,
allele, x2 = 0.00, d.f. = 1, P = 1.00).
Table 2 showed comparison among the present study and
the two previous studies of case-control association with
the SIGMAR1 gene. Values of allelic and genotypic distri-
bution of Gln2Pro polymorphism were almost similar
among the three studies. However, a difference of allelic
frequencies between controls and schizophrenics in Ishig-
uro's and Ohmori's study was 4.8 and 4.6 point, respec-
tively, and that of the present study was only 0.6 point.
Ishiguro's study revealed a marginal significant difference
between the groups, but Ohmori's one failed, suggesting a
negative result by the latter study may result from lack of
power to detect significance difference. However, it is pos-
sible that Ishiguro's result may be a false positive due to
population stratification, which is considered as unavoid-
able in such case-control association design studies.
To reduce possible population stratification and to verify
the negative results of association between schizophrenia
Table 1: Genotypic and allelic distribution of Gln2Pro polymorphism of the SIGMAR1 gene of schizophrenic patients and controls
Genotype (%) Allele (%)
Gln/Gln Gln/Pro Pro/Pro P Gln Pro P
Control (n = 206) 92(0.45) 94(0.45) 20(0.10) 278(0.68 134(0.32)
Schizophrenia (n = 199) 90(0.45) 91(0.46) 18(0.09) 0.97 271(0.68 127(0.32) 0.88
Hebephrenic (n = 107) 48(0.45) 49(0.46) 10(0.09) 0.99 145(0.68 69(0.32) 1
Paranoid (n = 90) 40(0.44) 42(0.47) 8(0.09) 0.97 122(0.68 58(0.32) 1
Table 2: Meta-analysis including present and previous association studies between the SIGMAR1 gene and schizophrenia
Genotype (%) Allele (%)
Gln/Gln Gln/Pro Pro/Pro p Gln Pro p
Present study Control (n = 206) 92(0.45) 94(0.45) 20(0.10) 278(0.68) 134(0.32)
Schizophrenia (n = 199) 90(0.45) 91(0.46) 18(0.09) 0.97 271(0.68) 127(0.32) 0.88
Ohmori et al. Control (n = 140) 75(0.54) 55(0.39) 10(0.07) 205(0.73) 75(0.27)
Schizophrenia (n = 129) 67(0.52) 43(0.33) 19(0.15) 0.12 177(0.69) 81(0.31) 0.25
Ishiguro et al. Control n = 433) 226(0.52) 172(0.40) 35(0.08) 624(0.72) 242(0.28)
Schizophrenia (n = 308) 135(0.44) 144(0.47) 29(0.09) 0.08 414(0.67) 202(0.33) 0.04
Total Control (n = 779) 393(0.50) 321(0.41) 65(0.08) 1107(0.71) 451(0.29)
Schizophrenia (n = 636) 292(0.46) 278(0.44) 66(0.10) 0.17 862(0.68) 410(0.32) 0.06Publish with BioMed Central    and   every 
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and the SIGMAR1 gene found by the present study, meta-
analysis was examined by getting data of the present and
the two previous studies [14,15] together, which com-
prised 779 controls and 636 schizophrenics in total
(Table 2). Meta-analysis revealed that there was no signif-
icant association in the genotype frequencies (x2 = 3.57,
d.f. = 2, P = 0.17) or allele frequencies (x2 = 3.57, d.f. = 1,
P = 0.06) of the SIGMAR1 gene with schizophrenia. The
power analysis showed that the present sample size had a
power of >0.9999 to detect significant allelic associations
and a power of 0.93 to detect genotypic associations,
given that the gene effect is small (the effective sample size
set at 0.1). Therefore, it is likely that the SIGMAR1 gene is
not associated with susceptibility to schizophrenia, and
genetic studies did not provide any additional support for
sigma receptor hypothesis for pathogenesis of schizophre-
nia. However, pharmacological studies suggested that
there are at least two subtypes of sigma receptors, type 1
and type 2 [17]. Although a gene for sigma receptor type
2 has not been cloned yet, the possibility remains that
genetic variance of sigma receptor type 2 or unknown sub-
types could precipitate development of schizophrenia.
Conclusions
The present study and meta-analysis including the previ-
ous two studies have suggested that the SIGMAR1 gene
does not confer susceptibility to schizophrenia.
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